Embryonic Stem Cell-derived Cardiomyocytes for the Treatment of Doxorubicin-induced Cardiomyopathy

Background: Doxorubicin (Dox) is a chemotherapy drug with limited application due to cardiotoxicity that may progress to heart failure. This study aims to evaluate the role of cardiomyocytes derived from mouse embryonic stem cells (CM-mESCs) in the treatment of Dox-induced cardiomyopathy (DIC) in mice.

Methods: The mouse embryonic stem cell (mESC) line E14TG2A was characterized by karyotype analysis, gene expression using RT-PCR and immunofluorescence. Cells were transduced with luciferase 2 and submitted to cardiac differentiation. Total conditioned medium (TCM) from the CM-mESCs was collected for proteomic analysis. To establish DIC in CD1 mice, Dox (7.5 mg/kg) was administered once a week for 3 weeks, resulting in a cumulative Dox dose of 22.5 mg/kg. At the fourth week, a group of animals was injected intramyocardially with CM-mESCs (8 × 10 cells). Cells were tracked by a bioluminescence assay, and the body weight, echocardiogram, electrocardiogram and number of apoptotic cardiomyocytes were evaluated.

Results: mESCs exhibited a normal karyotype and expressed pluripotent markers. Proteomic analysis of TCM showed proteins related to the negative regulation of cell death. CM-mESCs presented ventricular action potential characteristics. Mice that received Dox developed heart failure and showed significant differences in body weight, ejection fraction (EF), end-systolic volume (ESV), stroke volume (SV), heart rate and QT and corrected QT (QTc) intervals when compared to the control group. After cell or placebo injection, the Dox + CM-mESC group showed significant increases in EF and SV when compared to the Dox + placebo group. Reduction in ESV and QT and QTc intervals in Dox + CM-mESC-treated mice was observed at 5 or 30 days after cell treatment. Cells were detected up to 11 days after injection. The Dox + CM-mESC group showed a significant reduction in the percentage of apoptotic cardiomyocytes in the hearts of mice when compared to the Dox + placebo group.

Conclusions: CM-mESC transplantation improves cardiac function in mice with DIC.

Citing Articles

Cardioprotective effect of crude polysaccharide fermented by Trametes Sanguinea Lyoyd on doxorubicin-induced myocardial injury mice.

Shen C, Yang B, Huang L, Chen Y, Zhao H, Zhu Z BMC Pharmacol Toxicol. 2023; 24(1):1.

PMID: 36627724 PMC: 9832647. DOI: 10.1186/s40360-022-00641-y.

Modelling premature cardiac aging with induced pluripotent stem cells from a hutchinson-gilford Progeria Syndrome patient.

Monnerat G, Kasai-Brunswick T, Asensi K, Silva Dos Santos D, Barbosa R, Mesquita F Front Physiol. 2022; 13:1007418.

PMID: 36505085 PMC: 9726722. DOI: 10.3389/fphys.2022.1007418.

Anthracycline-induced cardiotoxicity and cell senescence: new therapeutic option?.

Seara F, Kasai-Brunswick T, Nascimento J, Campos-de-Carvalho A Cell Mol Life Sci. 2022; 79(11):568.

PMID: 36287277 PMC: 11803035. DOI: 10.1007/s00018-022-04605-7.

Transplantation of MITO cells, mitochondria activated cardiac progenitor cells, to the ischemic myocardium of mouse enhances the therapeutic effect.

Sasaki D, Abe J, Takeda A, Harashima H, Yamada Y Sci Rep. 2022; 12(1):4344.

PMID: 35318358 PMC: 8941106. DOI: 10.1038/s41598-022-08583-5.

Tissue-engineered human embryonic stem cell-containing cardiac patches: evaluating recellularization of decellularized matrix.

Hochman-Mendez C, de Campos D, Pinto R, Mendes B, Rocha G, Monnerat G J Tissue Eng. 2020; 11:2041731420921482.

PMID: 32742631 PMC: 7375712. DOI: 10.1177/2041731420921482.

References

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

Von Hoff D, Layard M, Basa P, Davis Jr H, Von Hoff A, Rozencweig M . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91(5):710-7. DOI: 10.7326/0003-4819-91-5-710. View

Mohammadi Gorji S, Karimpor Malekshah A, Hashemi-Soteh M, Rafiei A, Parivar K, Aghdami N . Effect of mesenchymal stem cells on Doxorubicin-induced fibrosis. Cell J. 2013; 14(2):142-51. PMC: 3584430. View

Tan G, Lou Z, Liao W, Zhu Z, Dong X, Zhang W . Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. PLoS One. 2011; 6(11):e27683. PMC: 3218026. DOI: 10.1371/journal.pone.0027683. View

Gava F, Zacche E, Ortiz E, Champion T, Bandarra M, Vasconcelos R . Doxorubicin induced dilated cardiomyopathy in a rabbit model: an update. Res Vet Sci. 2012; 94(1):115-21. DOI: 10.1016/j.rvsc.2012.07.027. View

Chen M, Lin Y, Xie S, Wu H, Wang J . Enrichment of cardiac differentiation of mouse embryonic stem cells by optimizing the hanging drop method. Biotechnol Lett. 2010; 33(4):853-8. DOI: 10.1007/s10529-010-0494-3. View

Merino H, Singla D . Notch-1 mediated cardiac protection following embryonic and induced pluripotent stem cell transplantation in doxorubicin-induced heart failure. PLoS One. 2014; 9(7):e101024. PMC: 4079560. DOI: 10.1371/journal.pone.0101024. View

Huang C, Zhang X, Ramil J, Rikka S, Kim L, Lee Y . Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010; 121(5):675-83. PMC: 2834271. DOI: 10.1161/CIRCULATIONAHA.109.902221. View

Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U . New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006; 41(3):389-405. DOI: 10.1016/j.yjmcc.2006.06.009. View

10.

Cao J, Li X, Chang N, Wang Y, Lei J, Zhao D . Dual-modular molecular imaging to trace transplanted bone mesenchymal stromal cells in an acute myocardial infarction model. Cytotherapy. 2015; 17(10):1365-73. DOI: 10.1016/j.jcyt.2015.05.003. View

11.

Singla D, Ahmed A, Singla R, Yan B . Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. Cell Transplant. 2012; 21(9):1919-30. PMC: 3402598. DOI: 10.3727/096368911X627552. View

12.

Raj S, Franco V, Lipshultz S . Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 2014; 16(6):315. DOI: 10.1007/s11936-014-0315-4. View

13.

Octavia Y, Tocchetti C, Gabrielson K, Janssens S, Crijns H, Moens A . Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52(6):1213-25. DOI: 10.1016/j.yjmcc.2012.03.006. View

14.

Salazar-Mendiguchia J, Gonzalez-Costello J, Roca J, Ariza-Sole A, Manito N, Cequier A . Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch Cardiol Mex. 2014; 84(3):218-23. DOI: 10.1016/j.acmx.2013.08.006. View

15.

Guo Q, Guo J, Yang R, Peng H, Zhao J, Li L . Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. Oxid Med Cell Longev. 2015; 2015:151972. PMC: 4446494. DOI: 10.1155/2015/151972. View

16.

Yu Q, Li Q, Na R, Li X, Liu B, Meng L . Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy. Mol Cell Biochem. 2013; 387(1-2):279-85. DOI: 10.1007/s11010-013-1894-1. View

17.

Morschbacher P, Alves Garcez T, Paz A, Magrisso A, Mello H, Rolim V . Treatment of dilated cardiomyopathy in rabbits with mesenchymal stem cell transplantation and platelet-rich plasma. Vet J. 2016; 209:180-5. DOI: 10.1016/j.tvjl.2015.11.009. View

18.

Sun Z, Schriewer J, Tang M, Marlin J, Taylor F, Shohet R . The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells. J Mol Cell Cardiol. 2015; 90:129-38. PMC: 4718883. DOI: 10.1016/j.yjmcc.2015.12.010. View

19.

Geiger S, Lange V, Suhl P, Heinemann V, Stemmler H . Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010; 21(6):578-90. DOI: 10.1097/CAD.0b013e3283394624. View

20.

Chen M, Fan Z, Liu X, Deng J, Zhang L, Rao L . Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure. Cell Biol Int. 2006; 30(7):576-82. DOI: 10.1016/j.cellbi.2006.03.002. View